Skip to main content

Merck KGaA sheds light on failed portion of phase 2 lupus trial, keeps sights on regulators

Submitted by admin on
snippet

Merck KGaA has shed more light on the failure of its lupus drug in one cohort of patients, while pointing to secondary endpoint readouts as proof that the candidate still deserves a shot at seeking approval.

Source
Fierce Biotech
Headline
https://www.fiercebiotech.com/biotech/merck-kgaa-sheds-light-failed-portion-pha…
News Tags
Merck KGaA
lupus
clinical trials
enpatoran

Merck KGaA fails midphase lupus trial, says totality of data support further development

Submitted by admin on
snippet

One of Merck KGaA’s leading immunology assets has flunked a phase 2 lupus trial. Despite the primary endpoint miss, Merck has concluded further development is warranted in light of responses seen in subgroups and a recent win in another form of the disease.

Source
Fierce Biotech
Headline
Merck KGaA fails midphase lupus trial, says totality of data support further de…
News Tags
Merck KGaA
clinical trials
lupus
enpatoran
Subscribe to enpatoran